362 related articles for article (PubMed ID: 25268566)
1. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study.
La Marca A; Grisendi V; Dondi G; Sighinolfi G; Cianci A
Gynecol Endocrinol; 2015 Jan; 31(1):52-6. PubMed ID: 25268566
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol.
Laganà AS; Barbaro L; Pizzo A
Arch Gynecol Obstet; 2015 May; 291(5):1181-6. PubMed ID: 25416201
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study.
Kachhawa G; Senthil Kumar KV; Kulshrestha V; Khadgawat R; Mahey R; Bhatla N
Int J Gynaecol Obstet; 2022 Aug; 158(2):278-284. PubMed ID: 34624138
[TBL] [Abstract][Full Text] [Related]
4. Myo-inositol vs. D-chiro inositol in PCOS treatment.
Formuso C; Stracquadanio M; Ciotta L
Minerva Ginecol; 2015 Aug; 67(4):321-5. PubMed ID: 25670222
[TBL] [Abstract][Full Text] [Related]
5. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
Fruzzetti F; Capozzi A; Canu A; Lello S
Gynecol Endocrinol; 2019 Jun; 35(6):506-510. PubMed ID: 30612488
[TBL] [Abstract][Full Text] [Related]
6. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Pizzo A; Laganà AS; Barbaro L
Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
[TBL] [Abstract][Full Text] [Related]
7. d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS.
Cianci A; Panella M; Fichera M; Falduzzi C; Bartolo M; Caruso S
Gynecol Endocrinol; 2015 Jun; 31(6):483-6. PubMed ID: 25893270
[TBL] [Abstract][Full Text] [Related]
8. Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles.
Dewailly D; Alebić MŠ; Duhamel A; Stojanović N
Hum Reprod; 2014 Nov; 29(11):2536-43. PubMed ID: 25267785
[TBL] [Abstract][Full Text] [Related]
9. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
Pustotina O; Myers SH; Unfer V; Rasulova I
Gynecol Obstet Invest; 2024; 89(2):131-139. PubMed ID: 38295772
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
11. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Nordio M; Proietti E
Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
[TBL] [Abstract][Full Text] [Related]
12. Anti-Müllerian Hormone Levels in Adolescence in Relation to Long-term Follow-up for Presence of Polycystic Ovary Syndrome.
Caanen MR; Peters HE; van de Ven PM; Jüttner AMFM; Laven JSE; van Hooff MHA; Lambalk CB
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1084-e1095. PubMed ID: 33351079
[TBL] [Abstract][Full Text] [Related]
13. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.
Galazis N; Galazi M; Atiomo W
Gynecol Endocrinol; 2011 Apr; 27(4):256-62. PubMed ID: 21142777
[TBL] [Abstract][Full Text] [Related]
14. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome.
Stabile G; Borrielli I; Artenisio AC; Bruno LM; Benvenga S; Giunta L; La Marca A; Volpe A; Pizzo A
J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):177-82. PubMed ID: 24814528
[TBL] [Abstract][Full Text] [Related]
15. Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
Stracquadanio M; Ciotta L; Palumbo MA
Gynecol Endocrinol; 2018 Jun; 34(6):495-501. PubMed ID: 29265900
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
Zhao H; Xing C; Zhang J; He B
Reprod Health; 2021 Aug; 18(1):171. PubMed ID: 34407851
[TBL] [Abstract][Full Text] [Related]
17. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
Unfer V; Porcaro G
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
[TBL] [Abstract][Full Text] [Related]
18. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
[TBL] [Abstract][Full Text] [Related]
19. Reflections on inositol(s) for PCOS therapy: steps toward success.
Nestler JE; Unfer V
Gynecol Endocrinol; 2015 Jul; 31(7):501-5. PubMed ID: 26177098
[TBL] [Abstract][Full Text] [Related]
20. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
Dinicola S; Chiu TT; Unfer V; Carlomagno G; Bizzarri M
J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
